Peritoneal (Abdominal Mesothelioma)
Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib
The Journal of Medical Research 2024 November [Link] Yufeng Wu, Yuhua Zhao, Limeng Yu, Ruilin Wang, Wen Feng, Yingxi Wu, Lili Wang, Haiyang Chen, Zhen He, Qiming Wang Abstract Malignant mesothelioma is a rare highly invasive tumour originating from the mesothelial cells of the pleura, peritoneum and pericardium. Malignant pleural mesothelioma (MPM) is the most…
Read MorePrognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers
Annals of Surgical Oncology 2024 November 13 [Link] Xin-Li Liang, Yan-Dong Su, Xin-Bao Li, Yu-Bin Fu, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li Abstract Objectives: This study was designed to explore the survival benefit factors of malignant peritoneal mesothelioma (MPM) patients after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and to…
Read MoreAscites as a Rare Manifestation of Malignant Peritoneal Mesothelioma: A Case Report
Cureus 2024 October 7 [Link] Sean Lief, Srihita Patibandla, Ali Z Ansari, Nilay Bhatt, Azouba Gulraiz, Samer M Beauti, Rashad Ali Abstract Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that originates from the mesothelial cells lining the parietal peritoneum or visceral peritoneum and extensively spreads within the abdominal cavity. It is a rare malignancy…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 204 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MorePotential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy
Cancer Biology & Medicine 2024 November 1 [Link] Heliang Wu, Yi Wang, Yulin Lin, Ru Ma, Xuemei Du, Yandong Su, Rui Yang, Zhiran Yang, Xinli Liang, Yinguang Zhang, Xiaoqing Liang, Zhonghe Ji Chunning Lai, Yajing Huang, Yan Li Abstract Objective: Malignant peritoneal mesothelioma (MPM) is a rare primary malignant tumor with an extremely poor prognosis…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 2024 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 2024 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MoreAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Scientific Reports 2024 October 29 [Link] Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M Dragovic Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of…
Read MoreAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Scientific Reports 2024 October 29 [Link] Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M Dragovic Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of…
Read MoreSystemic Therapy Options for Peritoneal Mesothelioma
Journal of the Comprehensive Cancer Network 2024 October [Link] Tawee Tanvetyanon, George R Simon Abstract Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials…
Read More